세계의 CRISPR 시장 예측(-2030년) : 오퍼링별, 유형별, 최종사용자별, 서비스별, 용도별, 지역별

The global CRISPR market is anticipated to reach USD 5.47 billion by 2030 from USD 3.21 billion in 2025, at a significant CAGR of 11.2%.

The CRISPR market is experiencing substantial growth, with a notable CAGR driven by its increasing adoption in research, clinical, and industrial applications. Several factors contribute to this market expansion, including the rising prevalence of genetic disorders, the growing use of CRISPR in drug discovery and gene therapy, and increased investments in biotechnology research and development. Additionally, advancements in CRISPR tools, improved delivery systems, and supportive regulatory developments further accelerate its integration into mainstream research and therapeutic pipelines.

"Products dominated the CRISPR market, by offering, in 2024."

Based on offerings, the CRISPR market is categorized into two main segments: products and services. The products segment includes CRISPR kits & enzymes, CRISPR libraries, and other products. The services segment encompasses gRNA synthesis & cell line development, screening & validation, and other services.

Users are increasingly seeking ongoing innovations, new product releases, and access to standardized, ready-to-use kits. These products are widely utilized in academic, clinical, and industrial research for applications in genome editing, functional genomics, and therapeutic development. This is a key factor driving market growth.

"The drug discovery & development application segment is anticipated to grow at a faster pace during the forecast period."

The application segment is divided into three categories: drug discovery & development, agriculture, and other applications. The largest segment is drug discovery & development, as CRISPR technology enhances early-stage research by facilitating the identification of connections between genes and diseases, as well as drug functions. This approach helps reduce timelines and increase the likelihood of success. Additionally, pharmaceutical & biotechnology companies are integrating CRISPR into their research and development processes to advance personalized medicine, gene therapy, and functional genomics, thereby enhancing the utilization of CRISPR technology.

"Pharmaceutical & biotechnology companies dominated the CRISPR products market, by end user, in 2024."

Based on end users, the CRISPR products market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and other end users. In 2024, pharmaceutical & biotechnology companies dominated this market. This dominance is driven by increasing investments in cell and gene therapies, as well as the demand for precise genetic tools for target identification and validation. These companies rely heavily on CRISPR technologies, and their strong financial capacity allows them to adopt advanced and customized CRISPR products at scale, further contributing to their significant market share.

"North America accounted for the largest share of the CRISPR market in 2024."

The market is divided by region into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America holds the largest share of the CRISPR market and is expected to maintain its lead. This dominance is attributed to the presence of prominent research institutions and significant investments in biotechnology. Additionally, the growing emphasis on cutting-edge medical research, personalized medicine, and precision medicine in the US gives North America a competitive advantage. The European CRISPR market is also experiencing steady growth, fueled by increased research and development efforts, particularly in countries such as Germany, the UK, and France.

In-depth interviews have been conducted with chief executive officers (CEOs), directors, and other executives from various key organizations operating in the CRISPR market.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side (70%) and Demand Side (30%)
• By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%)
• By Region: North America (35%), Europe (30%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)

The prominent players operating in the CRISPR market are Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), GenScript (US), Takara Bio (Japan), Creative Biogene (US), Fujian SunyBiotech Co., Ltd. (China), EditCo (US), Caribou Biosciences, Inc. (US), Lonza Group (Switzerland), Danaher Corporation (US), Revvity, Inc. (US), Hera BioLabs (US), OriGene Technologies, Inc. (US), Cellecta, Inc. (US), Mammoth Biosciences, Inc. (US), Applied StemCell (US), New England Biolabs Inc. (US), ToolGen Inc. (South Korea), GeneCopoeia, Inc. (US), Twist Bioscience Corporation (US), Synthego Corporation (US), eGenesis (US), Inscripta, Inc. (US), and Precision BioSciences, Inc. (US), among others.

Research Coverage:

The CRISPR market report is segmented based on offerings [products (CRISPR kits & enzymes, CRISPR libraries, and other products), services (gRNA synthesis & cell line development, screening & validation, and other services)], applications (drug discovery & development, agriculture, and other applications), and end users [product (pharmaceutical & biotechnology companies, academic & research institutes, and other end users), and service (pharmaceutical & biotechnology companies, academic & research institutes, and other end users)].

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the CRISPR market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. The report also covers new launches, collaborations, acquisitions, and recent developments associated with the CRISPR market.

Key Benefits of Buying the Report:

The report will assist both market leaders and new entrants by providing accurate revenue estimates for CRISPR and its subsegments. It will also help stakeholders better understand the competitive landscape, enabling them to position their businesses effectively and develop suitable go-to-market strategies. Additionally, this report will allow stakeholders to gauge the market dynamics and offer insights into the key drivers, restraints, opportunities, and challenges within the market.

The report provides insights into the following pointers:

• Analysis of key drivers (growing demand for CRISPR-based gene therapies, advancements in CRISPR technology, and growing government and private investments and funding for CRISPR technology), restraints (technical challenges associated with CRISPR technology), opportunities (development of new vaccines and treatments for genetic diseases and expanding industrial and agricultural applications of CRISPR), and challenges (regulatory hurdles for CRISPR advancements) influencing the growth of the market.
• Product Development/Innovation: In-depth analysis of emerging technologies in CRISPR, R&D activities, and new product launches in the CRISPR market.
• Market Development: The report provides detailed information about profitable markets and analyzes the market conditions across various regions.
• Market Diversification: Comprehensive information about new products, unexplored regions, recent updates, and investments in the CRISPR market.
• Competitive Assessment: Comprehensive evaluation of market shares, growth strategies, and product & service offerings of leading companies such as Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), and GenScript (US).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY RESEARCH
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 GLOBAL MARKET ESTIMATION
    • 2.2.1.1 Insights From Primary Experts
  • 2.2.2 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH)
• 2.3 MARKET GROWTH RATE PROJECTION
• 2.4 DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 CRISPR MARKET OVERVIEW
• 4.2 NORTH AMERICA: CRISPR MARKET, BY APPLICATION AND COUNTRY (2024)
• 4.3 CRISPR MARKET SHARE, BY END USER, 2025 VS. 2030

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing demand for CRISPR-based gene therapies
    • 5.2.1.2 Advancements in CRISPR technology
    • 5.2.1.3 Growing government and private investments and funding for CRISPR technology
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Technical challenges associated with CRISPR technology
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Development of new vaccines and treatments for genetic diseases
    • 5.2.3.2 Expanding industrial and agricultural applications of CRISPR
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Regulatory hurdles for CRISPR advancements
  • 5.2.5 TECHNOLOGY ANALYSIS
    • 5.2.5.1 Key technologies
      • 5.2.5.1.1 CRISPR-Cas systems
      • 5.2.5.1.2 gRNA design & optimization
      • 5.2.5.1.3 High-throughput CRISPR screening
    • 5.2.5.2 Complementary technologies
      • 5.2.5.2.1 Synthetic biology
      • 5.2.5.2.2 Single-cell genomics
      • 5.2.5.2.3 Next-generation sequencing
    • 5.2.5.3 Adjacent technologies
      • 5.2.5.3.1 Stem cell engineering
      • 5.2.5.3.2 Synthetic DNA & gene synthesis
      • 5.2.5.3.3 Microfluidics
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.4 SUPPLY CHAIN ANALYSIS
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 ECOSYSTEM ANALYSIS
• 5.7 PORTER'S FIVE FORCES ANALYSIS
  • 5.7.1 THREAT OF NEW ENTRANTS
  • 5.7.2 THREAT OF SUBSTITUTES
  • 5.7.3 BARGAINING POWER OF BUYERS
  • 5.7.4 BARGAINING POWER OF SUPPLIERS
  • 5.7.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.8 REGULATORY ANALYSIS
  • 5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.8.2 REGULATORY FRAMEWORK
    • 5.8.2.1 North America
      • 5.8.2.1.1 US
      • 5.8.2.1.2 Canada
    • 5.8.2.2 Europe
      • 5.8.2.2.1 Germany
      • 5.8.2.2.2 UK
      • 5.8.2.2.3 France
    • 5.8.2.3 Asia Pacific
      • 5.8.2.3.1 Japan
      • 5.8.2.3.2 China
    • 5.8.2.4 Latin America
      • 5.8.2.4.1 Brazil
    • 5.8.2.5 Middle East & Africa
      • 5.8.2.5.1 GCC Countries
      • 5.8.2.5.2 South Africa
• 5.9 PRICING ANALYSIS
  • 5.9.1 AVERAGE SELLING PRICE OF KITS AND REAGENTS, BY KEY PLAYER (2024)
  • 5.9.2 AVERAGE SELLING PRICE TREND OF CRISPR KITS & REAGENTS, BY KEY PLAYER, 2022-2024
  • 5.9.3 INDICATIVE PRICE TREND FOR CRISPR SERVICES
  • 5.9.4 AVERAGE SELLING PRICE TREND OF CRISPR KITS AND REAGENTS, BY REGION, 2024
• 5.10 PATENT ANALYSIS
• 5.11 KEY CONFERENCES & EVENTS, 2025-2026
• 5.12 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.12.2 CRISPR MARKET: BUYING CRITERIA
• 5.13 INVESTMENT & FUNDING SCENARIO
• 5.14 IMPACT OF AI ON CRISPR MARKET
• 5.15 TRADE ANALYSIS
  • 5.15.1 IMPORT DATA FOR KITS & REAGENTS, 2019-2023
  • 5.15.2 EXPORT DATA FOR KITS & REAGENTS, 2019-2023
  • 5.15.3 TRUMP IMPACT OVERVIEW: CRISPR MARKET
    • 5.15.3.1 Introduction
    • 5.15.3.2 Key tariff rates
    • 5.15.3.3 Price impact analysis
    • 5.15.3.4 Key Impact on various regions
      • 5.15.3.4.1 US
      • 5.15.3.4.2 Europe
      • 5.15.3.4.3 Asia Pacific
      • 5.15.3.4.4 Rest of the World
    • 5.15.3.5 End-use industry impact
      • 5.15.3.5.1 Pharmaceutical & biotech companies
      • 5.15.3.5.2 Contract research organizations (CROs)
      • 5.15.3.5.3 Academic & research institutes

6 CRISPR MARKET, BY OFFERING

• 6.1 INTRODUCTION
• 6.2 PRODUCTS
  • 6.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH
• 6.3 SERVICES
  • 6.3.1 GROWING DEMAND FOR PRECISE GENOME EDITING TOOLS IN RESEARCH AND CLINICAL APPLICATIONS TO BOOST MARKET

7 CRISPR PRODUCTS MARKET, BY TYPE

• 7.1 INTRODUCTION
• 7.2 CRISPR KITS & ENZYMES
  • 7.2.1 CRISPR KITS & ENZYMES SEGMENT TO DOMINATE CRISPR PRODUCTS MARKET DURING FORECAST PERIOD
• 7.3 CRISPR LIBRARIES
  • 7.3.1 INCREASING APPLICATIONS OF CRISPR LIBRARIES IN GENE EDITING TO DRIVE GROWTH
• 7.4 OTHER PRODUCTS

8 CRISPR PRODUCTS MARKET, BY END USER

• 8.1 INTRODUCTION
• 8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 8.2.1 INCREASING PRODUCT APPROVALS AND ROBUST CLINICAL PIPELINE TO PROPEL MARKET
• 8.3 ACADEMIC & RESEARCH INSTITUTES
  • 8.3.1 INCREASING FUNDING FOR GENOMIC PROJECTS TO PROPEL MARKET
• 8.4 OTHER END USERS

9 CRISPR MARKET, BY SERVICE

• 9.1 INTRODUCTION
  • 9.1.1 GRNA SYNTHESIS & CELL LINE DEVELOPMENT
    • 9.1.1.1 Emerging opportunities in CRISPR gRNA synthesis & cell line development to drive growth
  • 9.1.2 SCREENING & VALIDATION
    • 9.1.2.1 Rapid advancements in CRISPR technology to drive growth
• 9.2 OTHER SERVICES

10 CRISPR SERVICES MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 10.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH
• 10.3 ACADEMIC & RESEARCH INSTITUTES
  • 10.3.1 INCREASING INVESTMENTS IN GENOMIC PROJECTS TO PROPEL MARKET
• 10.4 OTHER END USERS

11 CRISPR MARKET, BY APPLICATION

• 11.1 INTRODUCTION
• 11.2 DRUG DISCOVERY & DEVELOPMENT
  • 11.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH
• 11.3 AGRICULTURE
  • 11.3.1 GROWING DEMAND FOR ENHANCED CROP TRAITS TO DRIVE GROWTH
• 11.4 OTHER APPLICATIONS

12 CRISPR MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 NORTH AMERICA
  • 12.2.1 MACROECONOMIC OUTLOOK OF NORTH AMERICA
  • 12.2.2 US
    • 12.2.2.1 Increasing demand for CRISPR products and services across various industries to drive growth
  • 12.2.3 CANADA
    • 12.2.3.1 Increasing demand for gene-editing technologies to boost growth
• 12.3 EUROPE
  • 12.3.1 MACROECONOMIC OUTLOOK OF EUROPE
  • 12.3.2 GERMANY
    • 12.3.2.1 Rapidly increasing biotechnology sector to support growth
  • 12.3.3 UK
    • 12.3.3.1 Significant government investments in genomics research to propel growth
  • 12.3.4 FRANCE
    • 12.3.4.1 Increasing demand for targeted therapies and personalized medicine to propel growth
  • 12.3.5 ITALY
    • 12.3.5.1 Increasing demand for innovative therapeutic solutions to drive growth
  • 12.3.6 SPAIN
    • 12.3.6.1 Increasing demand for precision medicine to drive growth
  • 12.3.7 REST OF EUROPE
• 12.4 ASIA PACIFIC
  • 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 12.4.2 CHINA
    • 12.4.2.1 Increasing investments in R&D to drive growth
  • 12.4.3 JAPAN
    • 12.4.3.1 Potential of CRISPR-based therapies in personalized medicine to present opportunities for market growth
  • 12.4.4 INDIA
    • 12.4.4.1 Increasing prevalence of genetic disorders to support growth
  • 12.4.5 REST OF ASIA PACIFIC
• 12.5 LATIN AMERICA
  • 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 12.5.2 BRAZIL
    • 12.5.2.1 Growing adoption of genome technologies to propel growth
  • 12.5.3 REST OF LATIN AMERICA
• 12.6 MIDDLE EAST & AFRICA
  • 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA

13 COMPETITIVE LANDSCAPE

• 13.1 INTRODUCTION
• 13.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CRISPR MARKET
• 13.3 REVENUE ANALYSIS, 2020-2024
• 13.4 MARKET SHARE ANALYSIS, 2024
• 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 13.5.1 STARS
  • 13.5.2 EMERGING LEADERS
  • 13.5.3 PERVASIVE PLAYERS
  • 13.5.4 PARTICIPANTS
  • 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 13.5.5.1 Company footprint
    • 13.5.5.2 Region footprint
    • 13.5.5.3 Product footprint
    • 13.5.5.4 Service footprint
    • 13.5.5.5 Application footprint
• 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 13.6.1 PROGRESSIVE COMPANIES
  • 13.6.2 RESPONSIVE COMPANIES
  • 13.6.3 DYNAMIC COMPANIES
  • 13.6.4 STARTING BLOCKS
  • 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES
    • 13.6.5.1 Detailed list of key startups/SMEs
    • 13.6.5.2 Competitive benchmarking of key startups/SMEs
• 13.7 COMPETITIVE SCENARIO
  • 13.7.1 PRODUCT LAUNCHES & APPROVALS
  • 13.7.2 DEALS
  • 13.7.3 EXPANSIONS
• 13.8 COMPANY VALUATION & FINANCIAL METRICS
• 13.9 BRAND/PRODUCT COMPARISON

14 COMPANY PROFILES

• 14.1 KEY PLAYERS
  • 14.1.1 THERMO FISHER SCIENTIFIC INC.
    • 14.1.1.1 Business overview
    • 14.1.1.2 Products/Services offered
    • 14.1.1.3 Recent developments
      • 14.1.1.3.1 Product/Service launches
      • 14.1.1.3.2 Deals
      • 14.1.1.3.3 Expansions
    • 14.1.1.4 MnM view
      • 14.1.1.4.1 Key strengths
      • 14.1.1.4.2 Strategic choices
      • 14.1.1.4.3 Weaknesses & competitive threats
  • 14.1.2 MERCK KGAA
    • 14.1.2.1 Business overview
    • 14.1.2.2 Products/Services offered
    • 14.1.2.3 Recent developments
      • 14.1.2.3.1 Deals
    • 14.1.2.4 MnM view
      • 14.1.2.4.1 Key strengths
      • 14.1.2.4.2 Strategic choices
      • 14.1.2.4.3 Weaknesses & competitive threats
  • 14.1.3 AGILENT TECHNOLOGIES, INC.
    • 14.1.3.1 Business overview
    • 14.1.3.2 Products/Services offered
    • 14.1.3.3 Recent developments
      • 14.1.3.3.1 Deals
      • 14.1.3.3.2 Expansions
    • 14.1.3.4 MnM view
      • 14.1.3.4.1 Key strengths
      • 14.1.3.4.2 Strategic choices
      • 14.1.3.4.3 Weaknesses & competitive threats
  • 14.1.4 GENSCRIPT
    • 14.1.4.1 Business overview
    • 14.1.4.2 Products/Services offered
    • 14.1.4.3 Recent developments
      • 14.1.4.3.1 Product/service approvals/launches
      • 14.1.4.3.2 Deals
      • 14.1.4.3.3 Expansions
  • 14.1.5 REVVITY
    • 14.1.5.1 Business overview
    • 14.1.5.2 Products/Services offered
    • 14.1.5.3 Recent developments
      • 14.1.5.3.1 Deals
  • 14.1.6 LONZA
    • 14.1.6.1 Business overview
    • 14.1.6.2 Products/Services offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Deals
  • 14.1.7 DANAHER CORPORATION
    • 14.1.7.1 Business overview
    • 14.1.7.2 Products/Services offered
    • 14.1.7.3 Recent developments
      • 14.1.7.3.1 Deals
  • 14.1.8 TAKARA BIO INC.
    • 14.1.8.1 Business overview
    • 14.1.8.2 Products/Services offered
    • 14.1.8.3 Recent developments
      • 14.1.8.3.1 Deals
  • 14.1.9 CREATIVE BIOGENE
    • 14.1.9.1 Business overview
    • 14.1.9.2 Products/Services offered
    • 14.1.9.3 Recent developments
      • 14.1.9.3.1 Product/service approvals/launches
  • 14.1.10 FUJIAN SUNYBIOTECH CO., LTD.
    • 14.1.10.1 Business overview
    • 14.1.10.2 Products/Services offered
  • 14.1.11 EDITCO
    • 14.1.11.1 Business overview
    • 14.1.11.2 Products/Services offered
    • 14.1.11.3 Recent financials
      • 14.1.11.3.1 Deals
  • 14.1.12 CARIBOU BIOSCIENCES, INC.
    • 14.1.12.1 Business overview
    • 14.1.12.2 Products/Services offered
    • 14.1.12.3 Recent developments
      • 14.1.12.3.1 Deals
  • 14.1.13 HERA BIOLABS
    • 14.1.13.1 Business overview
    • 14.1.13.2 Products/Services offered
  • 14.1.14 ORIGENE TECHNOLOGIES, INC.
    • 14.1.14.1 Business overview
    • 14.1.14.2 Products/Services offered
  • 14.1.15 CELLECTA, INC.
    • 14.1.15.1 Business overview
    • 14.1.15.2 Products/Services offered
• 14.2 OTHER PLAYERS
  • 14.2.1 MAMMOTH BIOSCIENCES, INC.
  • 14.2.2 APPLIED STEMCELL
  • 14.2.3 NEW ENGLAND BIOLABS
  • 14.2.4 TOOLGEN, INC.
  • 14.2.5 GENECOPOEIA, INC.
  • 14.2.6 TWIST BIOSCIENCE
  • 14.2.7 SYNTHEGO
  • 14.2.8 EGENESIS
  • 14.2.9 INSCRIPTA, INC.
  • 14.2.10 PRECISION BIOSCIENCES

15 APPENDIX

• 15.1 DISCUSSION GUIDE
• 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 15.3 CUSTOMIZATION OPTIONS
• 15.4 RELATED REPORTS
• 15.5 AUTHOR DETAILS